Form 4: Inmune Bio Director Granted 150,000 Stock Options

Inmune Bio, Inc. Director James Kelly Ganjei was granted 150,000 stock options with an exercise price of $1.48, vesting over three years.

Summary

• James Kelly Ganjei, a Director of Inmune Bio, Inc. (INMB), was granted 150,000 stock options.
• The options have an exercise price of $1.48 per share.
• The grant date for these options was December 1, 2025.
• The options will vest pro rata on a monthly basis over three years (1/36 per month), becoming 100% vested on the three-year anniversary of the grant date.
• The options were granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan.
• The expiration date for these options is November 23, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard compensation practice that aligns the director's interests with shareholder value over the long term, contingent on future stock performance. It is a positive for governance and incentive alignment, but not a direct operational or financial performance indicator.

Positives

• The grant of stock options aligns the director's long-term interests with those of the shareholders, incentivizing performance and value creation.
• The options were granted under an existing, approved stock incentive plan, indicating structured compensation practices.

Negatives

• The exercise of these options in the future could lead to a minor dilutive effect on existing shareholders.
• There is no immediate cash benefit to the director from this grant; value is contingent on future stock price appreciation.

Risks

• The value of the options is subject to the future market price fluctuations of Inmune Bio, Inc. common stock.
• The options will only become fully exercisable if the director remains with the company for the entire three-year vesting period.

Future Outlook

The vesting schedule of the options over three years indicates a long-term incentive structure for the director, aligning their future performance with the company's success and shareholder value creation.

Industry Context

The grant of stock options to directors is a common practice in publicly traded companies, particularly in the biotechnology sector, to attract, retain, and incentivize key personnel by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of stock options as a component of director compensation is a standard practice across various industries, including biotechnology, to align leadership incentives with shareholder interests.
• The vesting schedule over three years is typical for long-term incentive plans, promoting sustained commitment and performance.

Corporate Governance

Related Party Transactions

• The grant of 150,000 stock options to James Kelly Ganjei, a Director of Inmune Bio, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased director motivation to enhance stock value.
• Director (James Kelly Ganjei): Receives a long-term incentive tied to the company's stock performance, aligning personal financial interests with corporate success.

Next Steps

• The options will continue to vest monthly over the next three years, with full vesting by December 1, 2028.

Key Dates

Keywords

Inmune Bio, INMB, stock options, Form 4, insider transaction, director compensation, equity grant, James Kelly Ganjei